HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Teva Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Teva Intelligence Report

Generated from 36 signals · 4 evidence sources

Type

Company Intelligence Report

Generated

Aug 5, 2026

Confidence

Moderate Confidence · 72%

Evidence

213 items

Sources

30

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Teva maintains an active intelligence profile across Neurology, Anticonvulsant, Anesthesia, Neuromuscular Blockade, Oncology. 36 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 72% across 4 tracked sources. Highest-priority development: FDA TA — CANAGLIFLOZIN (ORIG). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Teva; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA TA — CANAGLIFLOZIN (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Cancer Clinical Trial Eligibility Criteria: Performance Status

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — ZIAC (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — GABAPENTIN (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA TA — CANAGLIFLOZIN (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Cancer Clinical Trial Eligibility Criteria: Performance Status

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — ZIAC (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — GABAPENTIN (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 5980 with buyer quality 4 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA TA — CANAGLIFLOZIN (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Cancer Clinical Trial Eligibility Criteria: Performance Status

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ZIAC (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — GABAPENTIN (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — CANAGLIFLOZIN (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Cancer Clinical Trial Eligibility Criteria: Performance Status

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ZIAC (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — GABAPENTIN (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Approval for Macitentan ANDA211187 by Teva Pharmaceuticals

    Cardiology · Pulmonary Arterial Hypertension

  • Teva's Budesonide and Formoterol Fumarate Dihydrate Receives FDA Approval

    Respiratory · Asthma/COPD

  • Teva's Gabapentin ANDA205807 Receives AP Status from FDA

    Neurology · Anticonvulsant

  • FDA Grants Approval for Glycerol Phenylbutyrate by Teva Pharmaceuticals

    Metabolic Disorders · Urea Cycle Disorders

  • FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

    Neurology · Multiple Sclerosis

  • Teva's Sugammadex Sodium Receives FDA Approval Status

    Anesthesia · Neuromuscular Blockade

  • FDA Approves Supplemental NDA for ZIAC by Teva

    Cardiovascular · Hypertension

  • Teva's Gabapentin ANDA205807 Receives Approval Status from FDA

    Neurology · Anticonvulsant

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.